All In Biotech

Drug Trial Radar · NCT06744205

A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older

A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older

Last checked: Nov 20, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,162 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,162

Actual

Start

Jan 6, 2025

Primary completion

May 22, 2026

Study completion May 22, 2026

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Dec 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular injection of different formulations of a hexavalent influenza messenger ribonucleic acid (mRNA) vaccine composed of differing dose levels of trivalent (TIV) mRNA hemagglutinin (HA) in combination with TIV mRNA-neuraminidase (NA) compared to an active control ((Fluzone standard-dose quadrivalent influenza vaccine (QIV-SD) or Fluzone high-dose quadrivalent influenza vaccine (QIV-HD) in adults 50 years of age and older.

Conditions

  • Influenza
  • Healthy Volunteers

Interventions

  • Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1Biological

    * Pharmaceutical form: solution for injection in a vial * Route of administration: Intramuscular injection

  • TIV mRNA-neuraminidase (NA)Biological

    * Pharmaceutical form: solution for injection in a vial * Route of administration: Intramuscular injection

  • TIV mRNA-HA Vaccine 2Biological

    * Pharmaceutical form: solution for injection in a vial * Route of administration: Intramuscular injection

  • Quadrivalent Influenza Standard Dose VaccineBiological

    * Pharmaceutical form: Liquid suspension for injection in pre-filled syringe * Route of administration: Intramuscular injection

  • Quadrivalent Influenza Vaccine High DoseBiological

    * Pharmaceutical form: Liquid suspension for injection in pre-filled syringe * Route of administration: Intramuscular injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with immediate unsolicited systemic adverse events (AEs)Time frame: Within 30 minutes after injection
  2. Number of participants with solicited injection site reactionsTime frame: Up to 7 days after injection
  3. Number of participants with solicited systemic reactionsTime frame: Up to 7 days after injection
  4. Number of participants with unsolicited AEsTime frame: Up to 28 days after injection
  5. Number of participants with medically attended adverse events (MAAEs)Time frame: Up to 180 days after injection
  6. Number of participants with serious adverse events (SAEs)Time frame: SAEs throughout the study (Up to approximately 12 months)
  7. Number of participants with adverse events of special interest (AESIs)Time frame: AESIs throughout the study (Up to approximately 12 months)
  8. Number of participants with out-of-range biological test resultsTime frame: Up to 8 days after injection
  9. Hemagglutinin inhibition (HAI) titersTime frame: At Day 1 and Day 29
  10. Individual HAI antibody (Ab) titer ratio D29/D01Time frame: At Day 1 and Day 29
  11. Seroconversion (HAI Ab titer)Time frame: At Day 1 and Day 29
  12. HAI Ab titer ≥ 40 (1/dil)Time frame: At Day 29
  13. Neuraminidase inhibition (NAI) titersTime frame: At Day 1 and Day 29
  14. Individual NAI Ab titer ratio D29/D01Time frame: At Day 1 and Day 29
  15. Seroconversion (NAI Ab titer)Time frame: At Day 1 and Day 29
  16. NAI Ab titer ≥ 40 (1/dil)Time frame: At Day 29
  17. 2-fold and 4-fold rise in NAI titersTime frame: Day 1 to Day 29

Locations

24 sites in 2 countries. Site status is shown where the registry gives one.

  • Accel Research Sites Network - Birmingham- Site Number : 8400008

    Birmingham, Alabama

  • AMR Mobile- Site Number : 8400022

    Mobile, Alabama

  • Alliance for Multispeciality Research - Clinical Research Consortium- Site Number : 8400015

    Tempe, Arizona

  • AMR Miami- Site Number : 8400021

    Coral Gables, Florida

  • Accel Research Sites Network - DeLand Clinical Research Unit- Site Number : 8400003

    DeLand, Florida

  • Alliance for Multispeciality Research - Fort Myers- Site Number : 8400013

    Fort Myers, Florida

  • Accel Research Sites - Maitland- Site Number : 8400007

    Maitland, Florida

  • Innovation Medical Research Center - Palmetto Bay- Site Number : 8400011

    Palmetto Bay, Florida

  • Accel Research Site - NeuroStudies.net, LLC - ERN - PPDS- Site Number : 8400001

    Decatur, Georgia

  • AMR - Chicago- Site Number : 8400012

    Oak Brook, Illinois

  • Alliance for Multispeciality Research - Newton- Site Number : 8400020

    Newton, Kansas

  • Alliance for Multispeciality Research - Wichita East- Site Number : 8400014

    Wichita, Kansas

  • Alliance for Multispeciality Research - Lexington- Site Number : 8400018

    Lexington, Kentucky

  • Boston Clinical Trials- Site Number : 8400009

    Boston, Massachusetts

  • ActivMed Practices & Research- Site Number : 8400005

    Methuen, Massachusetts

  • Quest Research Institute- Site Number : 8400010

    Farmington Hills, Michigan

  • Alliance for Multispeciality Research - Kansas City- Site Number : 8400019

    Kansas City, Missouri

  • AMR Las Vegas - Site Number : 8400016

    Las Vegas, Nevada

  • Coastal Carolina Research Center - North Charleston- Site Number : 8400002

    North Charleston, South Carolina

  • Alliance for Multispeciality Research - Knoxville- Site Number : 8400017

    Knoxville, Tennessee

  • Charlottesville Medical Research- Site Number : 8400004

    Charlottesville, Virginia

  • Investigational Site Number : 0360001

    Botany, New South Wales, Australia

  • Investigational Site Number : 0360003

    Bayswater, Victoria, Australia

  • Investigational Site Number : 0360002

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.